Dementia

...ba href=/dementia/a/b to paralysis to stroke.

Corbett said neuro-syphilis occurs only if regular syphilis goes untreated.

Syphilis is usually contracted through unprotected sex and is easily curable with antibiotics.

(Copyright 2007 by The Associated Press.

All Rights Reserved.) Don't Use Aspirin to Prevent Colon Cancer Exercise in Youth Keeps Hypertension Risk Low Antidepressants Help Stroke Patients' Thinking Depression More Severe Among Blacks FDA Tightens Warnings on Anemia Drugs Health Tip: Eating While on the Road Study Questions Antibiotic Guideline for Treatment of Pneumonia Stroke Patients Admitted on Weekends More Likely to Die All content © Copyright 2000 - 2007 WorldNow and WLOX, a Raycom Media Station.

All Rights Reserved.

For more information on this site, please read our Privacy Policy and Terms of Service.

...

...ba href=/dementia/a/b in the aged and even insomnia.

Almost half of Seroquel sales in 2006 were for disorders for which AstraZeneca has yet to gain regulatory approval, according to Datamonitor Plc, a London-based market research firm.

The other half was for approved indications such as treating schizophrenia and for bi-polar disorder, also known as manic depression, according to Terence McManus, a Datamonitor analyst.

The amount of off-label use is ``across the class,'' McManus said in an interview March 6.

Seroquel sales increased 24 percent in 2006 to $3.4 billion.

Revenue may jump 30 percent more this year to $4.4 billion, according to David Seemungal, an analyst at Standard & Poor's Equity in London.

He estimates that Seroquel sales of London- based AstraZeneca will peak in 2010 at $5.75 billion.

`Policies in Place' ``We have policies in place that provide direction around the appropriate promotion of our product,'' said Jim Minnick, an AstraZeneca spokesman.

Lilly's spokeswoman Carole Puls said the drugmaker doesn't promote off-label use.

Johnson & Johnson spokesman Srikant Ramaswami declined to comment on why off-label use is increasing.

``We promote our products only for their FDA-approved indications, and we support scientific and clinical studies that advance what is known about our products,'' he said.

J&J shares added 42 cents to $62.14 at 4:00 p.m.

in New York Stock Exchange composite trading.

Bristol-Myers...

...ba href=/dementia/a/b in the aged and even insomnia.

Almost half of Seroquel sales in 2006 were for disorders for which AstraZeneca has yet to gain regulatory approval, according to Datamonitor Plc, a London-based market research firm.

The other half was for approved indications such as treating schizophrenia and for bi-polar disorder, also known as manic depression, according to Terence McManus, a Datamonitor analyst.

The amount of off-label use is ``across the class,'' McManus said in an interview March 6.

Seroquel sales increased 24 percent in 2006 to $3.4 billion.

Revenue may jump 30 percent more this year to $4.4 billion, according to David Seemungal, an analyst at Standard & Poor's Equity in London.

He estimates that Seroquel sales of London- based AstraZeneca will peak in 2010 at $5.75 billion.

`Policies in Place' ``We have policies in place that provide direction around the appropriate promotion of our product,'' said Jim Minnick, an AstraZeneca spokesman.

Lilly's spokeswoman Carole Puls said the drugmaker doesn't promote off-label use.

Johnson & Johnson spokesman Srikant Ramaswami declined to comment on why off-label use is increasing.

``We promote our products only for their FDA-approved indications, and we support scientific and clinical studies that advance what is known about our products,'' he said.

J&J shares added 42 cents to $62.14 at 4:00 p.m.

in New York Stock Exchange composite trading.

Bristol-Myers...